• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Morphomolecular Pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma.胆管癌和肝细胞胆管癌起源细胞的形态分子病理学与基因组学见解
Am J Pathol. 2025 Mar;195(3):345-361. doi: 10.1016/j.ajpath.2024.08.014. Epub 2024 Sep 26.
2
The bile duct and liver cancer: ON-treatment surveillance of tumor evolution and response to systemic treatment (BILLIONSTARS) study.胆管癌和肝癌:肿瘤进展及全身治疗反应的治疗期监测(BILLIONSTARS)研究
BMC Cancer. 2025 Jun 11;25(1):1017. doi: 10.1186/s12885-025-14429-w.
3
Methylation aberrations and genomic instability synergistically drive the evolution of intrahepatic cholangiocarcinoma.甲基化异常与基因组不稳定性协同驱动肝内胆管癌的进展。
Epigenomics. 2025 Jul;17(10):661-674. doi: 10.1080/17501911.2025.2518919. Epub 2025 Jun 17.
4
PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice.PTEN 缺失通过小鼠中的极光激酶 A 诱导肝外胆管炎-胆管癌连续病变。
J Hepatol. 2024 Jul;81(1):120-134. doi: 10.1016/j.jhep.2024.02.018. Epub 2024 Feb 28.
5
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.可切除胆管癌的术后辅助化疗。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD012814. doi: 10.1002/14651858.CD012814.pub2.
6
CPZ: A Highly Sensitive Diagnostic Biomarker for the Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, Particularly in Poorly Differentiated Hepatocellular Carcinoma.CPZ:一种用于区分肝细胞癌和肝内胆管癌的高敏诊断生物标志物,尤其适用于低分化肝细胞癌。
Am J Surg Pathol. 2025 Jul 1;49(7):711-729. doi: 10.1097/PAS.0000000000002393. Epub 2025 Apr 7.
7
Transplant oncology: an emerging field in cancer care.移植肿瘤学:癌症治疗领域中的一个新兴领域。
Curr Opin Organ Transplant. 2025 Apr 10. doi: 10.1097/MOT.0000000000001221.
8
Deciphering cholangiocarcinoma heterogeneity and specific progenitor cell niche of extrahepatic cholangiocarcinoma at single-cell resolution.以单细胞分辨率解析肝外胆管癌的胆管癌异质性和特定祖细胞生态位。
J Hematol Oncol. 2025 Jun 23;18(1):66. doi: 10.1186/s13045-025-01716-z.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
10
The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review.门静脉栓塞在原发性肝胆癌手术治疗中的作用。一项系统评价。
Eur J Surg Oncol. 2017 Jan;43(1):32-41. doi: 10.1016/j.ejso.2016.05.026. Epub 2016 Jun 1.

本文引用的文献

1
Human Hepatocytes Can Give Rise to Intrahepatic Cholangiocarcinomas.人类肝细胞可引发肝内胆管癌。
Gastroenterology. 2024 Oct;167(5):1029-1032.e7. doi: 10.1053/j.gastro.2024.05.033. Epub 2024 Jun 10.
2
Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.整合多组学增强子活性谱分析鉴定不同病因胆管癌的治疗脆弱性。
Gut. 2024 May 10;73(6):966-984. doi: 10.1136/gutjnl-2023-330483.
3
Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing.利用单细胞 ATAC 测序对原发性肝癌中转录因子活性进行全基因组分析。
Cell Rep. 2023 Nov 28;42(11):113446. doi: 10.1016/j.celrep.2023.113446. Epub 2023 Nov 18.
4
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.全球肝细胞癌流行病学趋势:对筛查、预防和治疗的启示。
Nat Rev Clin Oncol. 2023 Dec;20(12):864-884. doi: 10.1038/s41571-023-00825-3. Epub 2023 Oct 26.
5
Gene Rearrangement and Expression of PRKACA and PRKACB Govern Morphobiology of Pancreatobiliary Oncocytic Neoplasms.基因重排和 PRKACA、PRKACB 的表达调控胰腺胆管嗜酸性细胞肿瘤的形态发生。
Mod Pathol. 2024 Jan;37(1):100358. doi: 10.1016/j.modpat.2023.100358. Epub 2023 Oct 21.
6
The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.肝吸虫相关胆管癌的特征:药物靶点的可能性洞察。
Recent Results Cancer Res. 2023;219:53-90. doi: 10.1007/978-3-031-35166-2_4.
7
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.分子靶向治疗在阿替利珠单抗/贝伐珠单抗治疗后进展的肝细胞癌和肝内胆管细胞癌患者中的应用。
J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28.
8
A marker gene-based method for identifying the cell-type of origin from single-cell RNA sequencing data.一种基于标记基因的方法,用于从单细胞RNA测序数据中识别细胞起源类型。
MethodsX. 2023 Apr 25;10:102196. doi: 10.1016/j.mex.2023.102196. eCollection 2023.
9
Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.成纤维板层样肝癌突变的类器官模型揭示了通过 BAP1 和 PRKAR2A 协同缺失的肝细胞转分化。
Nat Commun. 2023 May 3;14(1):2377. doi: 10.1038/s41467-023-37951-6.
10
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.欧洲肝脏研究学会-国际肝脏癌症协会《肝内胆管癌管理临床实践指南》。
J Hepatol. 2023 Jul;79(1):181-208. doi: 10.1016/j.jhep.2023.03.010. Epub 2023 Apr 20.

胆管癌和肝细胞胆管癌起源细胞的形态分子病理学与基因组学见解

Morphomolecular Pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma.

作者信息

Guest Rachel V, Goeppert Benjamin, Nault Jean-Charles, Sia Daniela

机构信息

Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.

Institute of Pathology, RKH Klinikum Ludwigsburg, Ludwigsburg, Germany; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.

出版信息

Am J Pathol. 2025 Mar;195(3):345-361. doi: 10.1016/j.ajpath.2024.08.014. Epub 2024 Sep 26.

DOI:10.1016/j.ajpath.2024.08.014
PMID:39341365
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11841493/
Abstract

Cholangiocarcinomas are a highly heterogeneous group of malignancies that, despite recent progress in the understanding of their molecular pathogenesis and clinical management, continue to pose a major challenge to public health. The traditional view posits that cholangiocarcinomas derive from the neoplastic transformation of cholangiocytes lining the biliary tree. However, increasing genetic and experimental evidence has recently pointed to a more complex, and nuanced, scenario for the potential cell of origin of cholangiocarcinomas. Hepatocytes as well as hepatic stem/progenitor cells are being considered as additional potential sources, depending on microenvironmental contexts, including liver injury. The hypothesis of potentially diverse cells of origin for cholangiocarcinoma, albeit controversial, is certainly not surprising given the plasticity of the cells populating the liver as well as the existence of liver cancer subtypes with mixed histologic and molecular features. This review carefully examines the current pathologic, genomic, and experimental evidence supporting the existence of multiple cells of origin of liver and biliary tract cancers, with particular focus on cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.

摘要

胆管癌是一组高度异质性的恶性肿瘤,尽管在对其分子发病机制和临床管理的理解方面取得了最新进展,但它们仍然对公共卫生构成重大挑战。传统观点认为,胆管癌源自胆管树内衬胆管细胞的肿瘤转化。然而,最近越来越多的基因和实验证据表明,胆管癌潜在起源细胞的情况更为复杂和微妙。根据包括肝损伤在内的微环境情况,肝细胞以及肝干/祖细胞也被视为额外的潜在来源。胆管癌潜在起源细胞多样的假说尽管存在争议,但鉴于肝脏中细胞的可塑性以及具有混合组织学和分子特征的肝癌亚型的存在,这当然并不奇怪。本综述仔细研究了支持肝和胆管癌存在多种起源细胞的当前病理、基因组和实验证据,特别关注胆管癌和肝细胞-胆管细胞癌。